Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Relapsed/Refractory CNS Lymphoma
NCT05117814Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in central nervous system lymphoma, sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT05117814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117814.